# GeparSixto (NCT01426880)

> Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT01426880
- Phase: PHASE2, PHASE3
- Status: COMPLETED
- Sponsor: GBG Forschungs GmbH
- Conditions: Tubular Breast Cancer Stage II; Mucinous Breast Cancer Stage II; Breast Cancer Female NOS; Invasive Ductal Breast Cancer; Tubular Breast Cancer Stage III; HER-2 Positive Breast Cancer; Inflammatory Breast Cancer Stage IV; Inflammatory Breast Cancer
- Interventions: Carboplatin; background treatment
- Enrollment: 595
- Primary outcome: Pathological complete response of breast and lymph nodes (ypT0 ypN0; primary endpoint)

## Commentary we found

- YouTube: 7
- X threads: 3
- Podcasts: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=geparsixto-nct01426880

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT01426880", "email": "<work email>"}; the inbox owner confirms by the emailed link.